Asterias Biotherapeutics, Inc. (AST) EPS Estimated At $-0.11; 4 Analysts Covering Fabrinet (FN)

July 18, 2018 - By Matt Emery

Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) Logo

Among 5 analysts covering Fabrinet (NYSE:FN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Fabrinet had 7 analyst reports since January 24, 2018 according to SRatingsIntel. Piper Jaffray maintained Fabrinet (NYSE:FN) rating on Monday, February 5. Piper Jaffray has “Buy” rating and $42.0 target. The company was downgraded on Wednesday, May 30 by Northland Capital. The stock has “Buy” rating by FBR Capital on Tuesday, May 8. Stifel Nicolaus maintained Fabrinet (NYSE:FN) rating on Wednesday, January 24. Stifel Nicolaus has “Buy” rating and $35 target. The firm has “Buy” rating given on Monday, January 29 by Northland Capital. The rating was maintained by Needham on Tuesday, February 6 with “Buy”. The firm earned “Buy” rating on Tuesday, April 17 by Northland Capital. See Fabrinet (NYSE:FN) latest ratings:

30/05/2018 Broker: Northland Capital Rating: Hold Downgrade
08/05/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $38 New Target: $40 Maintain
17/04/2018 Broker: Northland Capital Rating: Buy New Target: $35.0000 Maintain
06/02/2018 Broker: Needham Rating: Buy New Target: $40.0 Maintain
05/02/2018 Broker: Piper Jaffray Rating: Buy New Target: $42.0 Maintain
29/01/2018 Broker: Northland Capital Rating: Buy New Target: $37.0 Maintain
24/01/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $40 New Target: $35 Maintain

Analysts expect Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) to report $-0.11 EPS on August, 13.They anticipate $0.07 EPS change or 38.89% from last quarter’s $-0.18 EPS. After having $-0.09 EPS previously, Asterias Biotherapeutics, Inc.’s analysts see 22.22% EPS growth. The stock decreased 2.78% or $0.05 during the last trading session, reaching $1.75. About 98,798 shares traded. Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) has declined 52.94% since July 18, 2017 and is downtrending. It has underperformed by 65.51% the S&P500. Some Historical AST News: 25/04/2018 – ASTERIAS CITES FIRST SUBJECTS DOSING IN AST-VAC2 STUDY; 09/05/2018 – Asterias Biotherapeutics 1Q Loss/Shr 4c; 15/03/2018 Asterias Biotherapeutics 4Q Loss/Shr 12c; 14/05/2018 – Fidelity Management & Research Exits Position in Asterias; 21/04/2018 – DJ Asterias Biotherapeutics Inc Class , Inst Holders, 1Q 2018 (AST); 27/04/2018 – Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference; 25/04/2018 – ASTERIAS ANNOUNCES RELEASE PF CLINICAL GRADE LOT; 15/03/2018 – Asterias Biotherapeutics: Cash, Equivalents $21.6M as of Dec. 31; 16/05/2018 – Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medi; 25/04/2018 – Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2

More news for Asterias Biotherapeutics, Inc. (NYSEAMERICAN:AST) were recently published by:, which released: “Asterias up 9% premarket on updated data on AST-OPC1” on July 17, 2018.‘s article titled: “Asterias up 26% premarket on advancement of AST-VAC2” and published on July 11, 2018 is yet another important article.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company has market cap of $96.27 million. The firm develops therapeutic products in the areas of neurology and oncology. It currently has negative earnings. The Company’s clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.

Since February 6, 2018, it had 0 buys, and 13 sales for $17.08 million activity. Mitchell David T. also sold $1.20 million worth of Fabrinet (NYSE:FN) shares. Gill Harpal also sold $795,089 worth of Fabrinet (NYSE:FN) shares. Another trade for 27,188 shares valued at $1.00 million was made by Ng Toh-Seng on Friday, May 25.

Another recent and important Fabrinet (NYSE:FN) news was published by which published an article titled: “Potential Winners And Losers In The Optical Space From The Tariff Dispute” on July 18, 2018.

Investors sentiment increased to 0.96 in 2018 Q1. Its up 0.06, from 0.9 in 2017Q4. It increased, as 34 investors sold Fabrinet shares while 51 reduced holdings. 29 funds opened positions while 53 raised stakes. 36.25 million shares or 17.37% less from 43.87 million shares in 2017Q4 were reported. Koch Industries owns 17,277 shares. Geode Capital Lc stated it has 0% in Fabrinet (NYSE:FN). Vanguard Gru Incorporated has invested 0% in Fabrinet (NYSE:FN). Schwab Charles Mngmt Incorporated stated it has 255,470 shares or 0.01% of all its holdings. 3,011 are held by Ameritas Inv Prns. Jpmorgan Chase invested in 8,589 shares or 0% of the stock. Natixis Advsrs Lp reported 0.04% of its portfolio in Fabrinet (NYSE:FN). Profund Advisors Limited Com holds 6,612 shares or 0.01% of its portfolio. Oppenheimer & Inc invested in 18,911 shares. Teton Advsr holds 0.04% or 14,000 shares. 1,122 are held by Ls Advsr Limited Com. Schroder Invest Mgmt Group invested in 753,068 shares. Anchor Cap Advisors Ltd Liability Com stated it has 0.05% in Fabrinet (NYSE:FN). Frontier Management Lc has 0.06% invested in Fabrinet (NYSE:FN) for 264,430 shares. Public Employees Retirement Association Of Colorado holds 2,936 shares or 0% of its portfolio.

Fabrinet provides optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of optical communication components, modules and sub-systems, industrial lasers, medical devices, and sensors. The company has market cap of $1.48 billion. It offers a range of optical and electro-mechanical capabilities across the manufacturing process, including process design and engineering, supply chain management, manufacturing, printed circuit board assembly, packaging, integration, final assembly, and test. It has a 17.2 P/E ratio. The companyÂ’s products comprise switching products, such as reconfigurable optical add-drop multiplexers, optical amplifiers, modulators, and other optical components and modules that enable network managers to route voice, video, and data communications traffic through fiber optic cables at various wavelengths and speeds, and over various distances; tunable lasers, transceivers, and transponders; and active optical cables, which provide high-speed interconnect capabilities for data centers and computing clusters, as well as for Infiniband, Ethernet, fiber channel, and optical backplane connectivity.

Fabrinet (NYSE:FN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.